secwatch.observer — SEC 8-K summary
======================================

Issuer:     LAVA Therapeutics NV (—)
CIK:        0001840748
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001104659-25-016712
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LAVA Therapeutics cuts workforce ~30%, starts strategic review with advisor
---------------------------------------------------------------------------

- Workforce reduction of approx. 30%; expects $0.5M one-time costs, mostly Q1 2025.
- Board initiated strategic review to evaluate sale, merger, licensing, or other options.
- Cash, cash equivalents & investments $76.6M as of Dec 31, 2024 (unaudited).
- Will continue Phase 1 LAVA-1266 trial in AML/MDS and support Pfizer, J&J partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/0001104659-25-016712-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840748/000110465925016712/tm257490d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-016712

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer